An Open-label, Multi-center Phase I/Ib Dose Finding and Expansion Study of HRO761 as Single Agent and in Combinations in Patients With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors
Latest Information Update: 10 Apr 2025
At a glance
- Drugs HRO 761 (Primary) ; Irinotecan (Primary) ; Tislelizumab (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 10 Dec 2024 Planned End Date changed from 31 Jan 2030 to 30 May 2029.
- 10 Dec 2024 Planned primary completion date changed from 30 Jan 2030 to 30 May 2029.
- 02 Apr 2024 Planned End Date changed from 11 Aug 2026 to 31 Jan 2030.